Illumina VeriSeq NIPT Solution
Illumina has launched the VeriSeq NIPT Solution v2, a CE-IVD, next-generation sequencing-based approach to noninvasive prenatal testing. The new version allows laboratories to scan for a wider range of chromosomal and sub-chromosomal conditions associated with birth defects. The firm said that the assay provides information about fetal chromosomal status as early as 10 weeks of gestation using a single maternal blood draw, and offers an option to screen for aneuploidy in all autosomes, chromosomes X and Y, and partial deletions and duplications greater than 7 Mb across the genome. According to Illumina, the assay is currently available in Europe and South Africa; registration is pending in Australia, Israel, and New Zealand.
Thermo Fisher Scientific Orbitrap Exploris 480, Orbitrap Eclipse Tribrid Instrument, and Mass Spectrometry Software
Thermo Fisher Scientific launched multiple mass spectrometry instruments and software this week.
The firm's Orbitrap Exploris 480 mass spectrometer allows more rigorous high-throughput protein identification, quantitation, and structural characterization. According to the firm, the mass spectrometer has a smaller footprint than previous instrument versions and maintains high resolution, mass accuracy, and spectral quality.
Thermo said that its new Orbitrap Eclipse Tribrid mass spectrometer has improved sensitivity over previous generations and can better characterize and quantify complex biomolecules and biological systems.
Users can combine both new instruments with Thermo's FAIMS Pro interface, a differential ion mobility device that improves selectivity and increases productivity across a range of proteomics workflows.
Thermo's new TraceFinder Software 5.0 offers quicker and easier access to information from the firm's TSQ Quadrupole and Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometry platforms. In addition, Thermo's Almanac web-based application allows users to remotely access instruments to monitor their run status and data acquisition.
Tempus Integrated Molecular Evaluation (TIME) Trial
During this week's American Society of Clinical Oncology meeting, Tempus introduced its Tempus Integrated Molecular Evaluation (TIME) Trial. This service features a proprietary technology platform that analyzes molecular and clinical data on cancer patients in real time to match people to clinical trials. The firm's TIME Trial sends patients only to prequalified academic and community cancer centers to allow those who qualify to enroll immediately.
For more new products and services, please visit the New Products page on our website.